Supervisor Database Search
Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameDr Mark Sherlock
Department:Department of Endocrinology
Organisation:Trinity College Dublin
- genetics, genomics and molecular biology
- physiology and non-communicable disease
Other Research Fields:
Endocrinology, Pituitary and Adrenal Disease
Postgrad Medical Specialties
- Clinical Trials
Our research group is based between Tallaght Hospital/ Trinity College, Dublin and Beaumont Hospital/ RCSI, Dublin (Professor Chris Thompson). Our group focuses on studies related to adrenal disease, pituitary disease and disorders of salt and water balance.
Current ongoing work builds on prior published work in areas including:
2. Pituitary tumours and response to therapies
3. Morbidity and mortality outcomes in patients with hypopituitarism
4. Optimisation of glucocorticoid replacement in patients with adrenal insufficiency
5. Hyponatraemia – pathogenesis and treatment
We have a strong track record of publication in the areas above. As a group we collaborate with colleagues in Ireland (Cork and Belfast), UK (Birmingham), Germany and Spain.
Hypopituitarism is associated with increased mortality and morbidity. At present the underlying mechanisms leading to this adverse phenotype are not clear. Patients with hypopituitarism receive hormone replacement therapy in the form of growth hormone, hydrocortisone, sex steroids and thyroxine. Markers of adequate replacement are crude for a number of these therapies at present and our ongoing work looks at ways to optimise replacement strategies and assess newer markers of of replacement adequacy in particular when assessing cortisol replacement.
We aim to prospectively follow patients with pituitary disease to assess the metabolic impact of hypopituitarism. In particular, detailed assessment of cortisol metabolism and markers of cortisol replacement adequacy will be measured as well as the assessment of interventions to optimise glucocorticoid replacement.
It is expected that results of this research will lead to high impact publications, offer novel insights into impact of cortisol deficiency and replacement in hypopituitarism and help identify novel biomarkers to aid with optimisation of therapy. This project would be particularly suited to those interested in Endocrinology and would offer an opportunity to devlelop as a clinician scientist as the research programme will involve both clinical and molecular biology training.
Other potential projects within the unit include:
• Assessment of biomarkers of tumour growth/ aggressiveness and response to treatment in pituitary tumours
• Improving diagnosis and treatment in patients with hyponatraemia
• Assessment of cardiovascular risk and outcomes in patients with acromegaly